Survival Analysis Three-year Follow-up of Pacients with Head and Neck Cancer

Česká verzia

Authors: E. Malá ¹; E. Vejražková ²; M. Vošmik ³ ; J. Novosad ¹; L. Sobotka ⁴
Authors place of work: Ústav klinické imunologie a alergologie, FN Hradec Králové ¹; IV. interní hematologická klinika LF UK a FN Hradec Králové ²; Klinika onkologie a radioterapie LF UK a FN Hradec Králové ³; III. interní gerontometabolická klinika LF UK a FN Hradec Králové ⁴
Published in the journal: Klin Onkol 2016; 29(1): 39-51
Category: Original Articles
doi: https://doi.org/10.14735/amko201639

Summary

Background:
Patients with head and neck cancer are predominantnly at the risk for malnutrition. Monitoring of nutritional status and pre-treatment variables can favorably observe many prognostic indicators for overall survival in head and neck cancer before and during oncological treatment up to three years in head and neck cancer pacients.

Materials and Methods:
In 726 patients diagnosed head and neck cancer patients with curative intent, were collected data according to the monitoring scheme of observation. As a clinical important of uninteded weight loss was defined weight loss ≥ 10% in input (T0). Differences in groups were analysed by Cox’s regression with adjustments for important demografic and tumor-related data.

Results:
The acceptanceof the percutaneous endoscopic gastrostomy was a key factorfor less complications andto improvetoleranceof anticancer treatment. Men-smokers have the highestrisk of cardiovascular mortality. Men-stop-smokers have the most significant life extension of 11 to 22 months; p < 0.007. Men-non-smokers have a life extension of 15 to 23 months (p < 0.005) and having its lowest cardiovascular mortality (11%). Women tolerate cancer better, have minor subjective complaints and a lower number of complications but significantly higher consumption of antidepressants (p < 0.003). While men have higher analgesic consumption (p < 0.001). Weight loss > 10% significantly correlates with the clinical manifestations of malnutrition and isassociated with an increasein complications and mortality dependent cancer (p < 0.008).

Conclusion:
Consistent assessment of nutritional status with early interventionis considered as an essential part of comprehensive anticancer treatment. An independent risk factor for cancer-dependent mortality is considered weight loss of > 5% with a BMI < 21 at time T0 or weight loss > 10% weight T0 in BMI 21– 29 and continuing weight loss toT12 and also BMI ≥ 30. The highest-risk profile has a male sex-smoker, age > 63, hypopharyngeal carcinoma, stage III– IV, weight loss of > 10% and non-acceptance of percutaneous endoscopic gastrostomy. Another long-term observation of monitored nutritional status with intervention, clinical status and quality of life are needed.

Key words:
survival analysis – head and neck cancer – HNC – malnutrition – weight loss

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
17. 7. 2015

Accepted:
20. 9. 2015

Zdroje

1. Zvolsky M, Nechanska B, Kralikova E. The use of diagnoses related to tobacco use in the Czech Republic. Cas Lek Cesk 2012; 151(12): 573– 578.

2. Dusek L, Pavlik T, Májek O et al. Odhady incidence, prevalence a počtu onkologických pacientů léčených protinádorovou terapií v letech 2015– 2020, analýza Národního onkologického registru. Klin Onkol 2015; 28(1): 30– 43. doi: 10.14735/ amko201530.

3. Dusek L, Muzik J, Gelnarova E et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010; 23(5): 311– 324.

4. Dusek L, Muzik J, Maluskova D et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2014; 27(6): 406– 423. doi: 10.14735/ amko2014406.

5. Čelakovský P, Betka J, Plzák J (eds). Krční metastázy. Havlíčkův Brod: Tobiáš 2012: 17– 317.

6. Elia M, Stratton R. On the ESPEN guidelines for nutritional screening 2002. Clin Nutr 2004; 23(1): 131– 132.

7. Fearon KC. The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient-focused outcomes. Clin Nutr 2012; 31(5): 577– 582. doi: 10.1016/ j.clnu.2012.06.012.

8. Kondrup J, Allison SP, Elia M et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22(4): 415– 421.

9. Lochs H, Allison SP, Meier R et al. Introductory to the ESPEN Guidelines on Enteral Nutrition: terminology, definitions and general topics. Clin Nutr 2006; 25(2): 180– 186.

10. Chroust K, Finek J, Zemanek P et al. Experience in data management of the clinical retrospective project in Czech and Slovak oncology centres (IKARUS Project). Klin Onkol 2009; 22(4): 163– 167.

11. Soeters PB, Schols AM. Advances in understanding and assessing malnutrition. Curr Opin Clin Nutr Metab Care 2009; 12(5): 487– 494. doi: 10.1097/ MCO.0b013e32832da243.

12. Sobotka L (ed.). Basics in clinical nutrition. Praha: Galén 2004: 16– 723.

13. Soeters MR, Soeters PB, Schooneman MG et al. Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation. Am J Physiol Endocrinol Metab 2012; 303(12): E1397– E1407. doi: 10.1152/ ajpendo.00397.2012.

14. Younes RN, Noguchi Y. Pathophysiology of cancer cachexia. Rev Hosp Clin Fac Med Sao Paulo 2000; 55(5): 181– 193.

15. Skipworth RJ, Stewart GD, Dejong CH et al. Pathophysiology of cancer cachexia: much more than host-tumour interaction? Clin Nutr 2007; 26(6): 667– 676.

16. Smiechowska J, Utech A, Taffet G et al. Adipokines in patients with cancer anorexia and cachexia. J Investig Med 2010; 58(3): 554– 559. doi: 10.231/ JIM.0b013e3181-cf91ca.

17. Soeters PB, Sobotka L. The pathophysiology underlying the obesity paradox. Nutrition 2012; 28(6): 613– 615. doi: 10.1016/ j.nut.2011.10.010.

18. Bozzetti F, Cozzaglio L, Gavazzi C et al. Total nutritional manipulation in humans: report of a cancer patient. Clin Nutr 1996; 15(4): 207– 209.

19. Bozzetti F. Continuing: biology of cachexia. J Natl Cancer Inst 1999; 91(12): 1077– 1078.

20. Bozzetti F. Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 2009; 17(3): 279– 284. doi: 10.1007/ s00520-008-0476-3.

21. Bozzetti F. Nutritional support of the oncology patient. Crit Rev Oncol Hematol 2013; 87(2): 172– 200. doi: 10.1016/ j.critrevonc.2013.03.006.

22. Bozzetti F. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr 2013; 32(5): 876. doi: 10.1016/ j.clnu.2013.07.003.

23. Bozzetti F. Nutrition, hydration, and patient‘s preferences at the end of life. Support Care Cancer 2015; 23(6): 1487– 1488. doi: 10.1007/ s00520-014-2591-7.

24. Socher SH, Martinez D, Craig JB et al. Tumor necrosis factor not detectable in patients with clinical cancer cachexia. J Natl Cancer Inst 1988; 80(8): 595– 598.

25. Solheim TS, Laird BJ. Evidence base for multimodal therapy in cachexia. Curr Opin Support Palliat Care 2012; 6(4): 424– 431. doi: 10.1097/ SPC.0b013e328359b668.

26. Solheim TS, Blum D, Fayers PM et al. Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod? – analysis from a multicenter cross sectional study. Acta Oncol 2014; 53(4): 539– 546. doi: 10.3109/ 0284186X.2013.823239.

27. Linkos.cz [internetová stránka]. Česká onkologická spo-lečnost ČLS JEP, Česká republika; c2000-06. Dostupné z:www.linkos.cz.

28. Cancer.org [homepage on the Internet]. American Cancer Society. Available from: www.cancer.org.

29. Haškovcová H (ed.). Lékařská etika. Praha: Galén 2002: 272.

30. Wood K. Audit of nutritional guidelines for head and neck cancer patients undergoing radiotherapy. J Hum Nutr Diet 2005; 18(5): 343– 351.

31. Zadák Z (ed.). Výživa v intenzivní péči. Praha: Grada publishing 2008: 542.

32. Ptáček R, Bartůněk P et al (eds). Etické problémy medicína na prahu 21. století. Praha: Grada publishing 2014: 520.

33. Sochor M, Slama O. Management chronické a akutní bolesti u pacientů s nádorovými chorobami. Klin Onkol 2015; 28(2): 94– 98.

34. Lis CG, Gupta D, Lammersfeld CA et al. Role of nutritional status in predicting quality of life outcomes in cancer – a systematic review of the epidemiological literature. Nutr J 2012; 11: 27. doi: 10.1186/ 1475-2891-11-27.

35. Arends J, Bodoky G, Bozzetti F et al. ESPEN Guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006; 25(2): 245–259.

36. Lee JH, Machtay M, Unger LD et al. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124(8): 871– 875.

37. Loser C, Aschl G, Hebuterne X et al. ESPEN guidelines on artificial enteral nutrition – percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005; 24(5): 848– 861.

38. Nicholl MB, Lyons DA, Wheeler AA et al. Repeat PEG placement is safe for head and neck cancer patients. Am J Otolaryngol 2014; 35(2): 89– 92. doi: 10.1016/ j.amjoto.2013.12.001.

39. Raykher A, Correa L, Russo L et al. The role of pretreatment percutaneous endoscopic gastrostomy in facilitating therapy of head and neck cancer and optimizing the body mass index of the obese patient. JPEN J Parenter Enteral Nutr 2009; 33(4): 404– 410. doi: 10.1177/ 0148607108327525.

40. Reilly JJ. Does nutrition management benefit the head and neck cancer patient? Oncology (Williston Park) 1990; 4(6): 105– 115.

41. Schutz T, Valentini L, Herbst B et al. ESPEN guidelines on enteral nutrition – summary. Z Gastroenterol 2006; 44(8): 683– 684.

42. Schutz T, Herbst B, Koller M. Methodology for the development of the ESPEN Guidelines on enteral nutrition. Clin Nutr 2006; 25(2): 203– 209.

43. Vassilopoulos PP, Filopoulos E, Kelessis N et al. Competent gastrostomy for patients with head and neck cancer. Support Care Cancer 1998; 6(5): 479– 481.

44. Weijs TJ, Berkelmans GH, Nieuwenhuijzen GA et al.Routes for early enteral nutrition after esophagectomy. A systematic review. Clin Nutr 2015; 34(1): 1– 6. doi: 10.1016/ j.clnu.2014.07.011.

45. Pai PC, Chuang CC, Tseng CK et al. Impact of pretreatment body mass index on patients with head-and-neck cancer treated with radiation. Int J Radiat Oncol Biol Phys 2012; 83(1): e93– e100. doi: 10.1016/ j.ijrobp.2011.11.071.

46. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47(11): 1245– 1251.

47. Charlson M, Wells MT, Ullman R et al. The Charlson comorbidity index can be used prospectively to identify patients who will incur high future costs. PLoS One 2014; 9(12): e112479. doi: 10.1371/ journal.pone.0112479.

48. Karnofsky DA, Ellison RR, Golbey RB. Selection of patients for evaluation of chemotherapeutic procedures in advanced cancer. J Chronic Dis 1962; 15: 243– 249.

49. Takenaka Y, Takemoto N, Nakahara S et al. Prognostic significance of body mass index before treatment for head and neck cancer. Head Neck 2015; 37(10): 1518– 1523. doi: 10.1002/ hed.23785.

50. Carmack CL, Basen-Engquist K, Gritz ER. Survivors at higher risk for adverse late outcomes due to psychosocial and behavioral risk factors. Cancer Epidemiol Biomarkers Prev 2011; 20(10): 2068– 2077. doi: 10.1158/ 1055-9965.EPI-11-0627.

51. Silander E, Nyman J, Bove M et al. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck 2012; 34(1): 1– 9. doi: 10.1002/ hed.21700.

52. So WK, Chan RJ, Chan DN et al. Quality-of-life among head and neck cancer survivors at one year after treatment – a systematic review. Eur J Cancer 2012; 48(15): 2391– 2408. doi: 10.1016/ j.ejca.2012.04.005.

53. Nelke KH, Pawlak W, Gerber H et al. Head and neck cancer patients‘ quality of life. Adv Clin Exp Med 2014; 23(6): 1019– 1027. doi: 10.17219/ acem/ 37361.

54. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365– 376.

55. Bozzetti F. Quality of life and enteral nutrition. Curr Opin Clin Nutr Metab Care 2008; 11(5): 661– 665. doi: 10.1097/ MCO.0b013e32830a7099.

56. Petruson KM, Silander EM, Hammerlid EB. Quality of life as predictor of weight loss in patients with head and neck cancer. Head Neck 2005; 27(4): 302– 310.

57. Ravasco P, Monteiro-Grillo I, Marques VP et al. Quality of life in gastrointestinal cancer: what is the impact of nutrition? Acta Med Port 2006; 19(3): 189– 196.

58. Sat-Munoz D, Moran MA, Solano-Murillo P et al. EORTC QLQ-C30 questionnaire role as predictor for malnutrition risk in head and neck cancer Mexican patients. Nutr Hosp 2012; 27(2): 477– 482. doi: 10.1590/ S0212-16112012000200019.

59. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991; 67 (Suppl 3):844– 850.

60. Aaronson NK, Snyder C. Using patient-reported outcomes in clinical practice: proceedings of an International Society of Quality of Life Research conference. Qual Life Res 2008; 17(10): 1295. doi: 10.1007/ s11136-008-9422-6.

61. Bjordal K, Hammerlid E, Ahlner-Elmqvist M et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999; 17(3): 1008– 1019.